Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy

Area of Science:

• Molecular Biology
• Oncology
• Gene Therapy

Background:

• The BCR-ABL1 oncogene drives chronic myeloid leukemia (CML) development and maintenance.
• Current tyrosine kinase inhibitor (TKI) treatments offer good prognoses but require lifelong adherence and face resistance.
• Persistent leukemic stem cells and TKI side effects necessitate novel therapeutic strategies.

Purpose of the Study:

• To explore the potential of gene-editing technologies, specifically CRISPR, for treating CML.
• To evaluate CRISPR/Cas9 as a definitive treatment by permanently inactivating the BCR-ABL1 oncogene.

Main Methods:

• Review of CRISPR (clustered regularly interspaced short palindromic repeats) technology.
• Description of CRISPR/Cas9's mechanism for inducing sequence-specific DNA double-strand breaks.
• Analysis of CRISPR's capacity for permanent oncogene knockout.

Main Results:

• CRISPR/Cas9 enables precise DNA targeting to disrupt oncogenic sequences.
• This technology offers the potential for complete and permanent inactivation of the BCR-ABL1 oncogene.
• Unlike TKIs, CRISPR/Cas9 aims for a definitive cure rather than temporary inactivation.

Conclusions:

• CRISPR/Cas9 gene editing presents a promising therapeutic alternative for CML.
• This approach could offer a definitive treatment by permanently eliminating the oncogenic driver.
• Further advances in genome editing may revolutionize CML treatment paradigms.